[Read More] Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R
Important Notice These products are: Not approved for human consumption Not approved for diagnostic or therapeutic use Not intended for medical application Intended strictly for controlled laboratory research Researchers should use peptide materials only within lawful laboratory environments
(Study: Frias et al., 2021) Dual Agonism: Tirzepatide's distinctive dual mechanism of action combines GLP-1 receptor activation with glucagon receptor activation, potentially resulting in even more pronounced weight loss compared to traditional GLP-1 RAs
For some, they see results within weeks
What's the dose in trials
Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients